Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957252 · ClinicalTrials.gov registry record
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by Nanostics.
- Active
- Registry status
- 2,800
- Enrollment target
- 3
- Study locations
NCT03957252: Active study of Prostate Cancer, sponsored by Nanostics.
NCT03957252 is a study of Prostate Cancer that is active but no longer recruiting, run by Nanostics. The registered enrollment target is 2,800 participants, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (363% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03957252, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Nanostics.
- ACTIVE NOT RECRUITING
- Registry status
- 2,800 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to determine the accuracy of blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater or equal to 3 ng/mL.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood test: ClarityDX Prostate
Study Locations (3)
Alberta
- Prostate Cancer Centre - Calgary
- Kipnes Urology Centre - Edmonton
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03957252
The ClinicalTrials.gov registry entry for NCT03957252 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (363% higher). The listed sponsor is Nanostics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood test: ClarityDX Prostate is the first listed.
NCT03957252 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Alberta, Maryland.
Frequently Asked Questions
What is clinical trial NCT03957252 about?
NCT03957252 is a clinical study titled "Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer". This study is designed to determine the accuracy of blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater or equal to 3 ng/mL.
What is the current status of trial NCT03957252?
This trial is currently active not recruiting. The enrollment target is 2,800 participants. The study started on 2019-06-06. Estimated completion is 2027-03.
What conditions does trial NCT03957252 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03957252?
The interventions under investigation include: Blood test: ClarityDX Prostate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03957252?
This trial is sponsored by Nanostics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03957252 being conducted?
This trial has 3 study locations across Maryland, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.